Inovio Pharmaceuticals, Inc. $INO Holdings Decreased by Stonepine Capital Management LLC

Key Points

• Stonepine Capital Management LLC reduced its stake in Inovio Pharmaceuticals by 50.6%, selling 531,669 shares and retaining approximately 518,331 shares, which now represent 0.8% of its investment portfolio.
• Inovio Pharmaceuticals reported a quarterly loss of ($0.61) EPS, slightly beating analyst expectations of (0.63), with a consensus forecast of -4.23 EPS for the current fiscal year.
• Analysts have differing views on Inovio Pharmaceuticals, with a consensus rating of "Moderate Buy" and a target price of $8.80, despite one firm recently downgrading its rating to "sell."

Stonepine Capital Management LLC trimmed its position in shares of Inovio Pharmaceuticals, Inc. (NASDAQ:INO - Free Report) by 50.6% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 518,331 shares of the biopharmaceutical company's stock after selling 531,669 shares during the period. Inovio Pharmaceuticals comprises about 0.8% of Stonepine Capital Management LLC's portfolio, making the stock its 24th biggest position. Stonepine Capital Management LLC owned 1.41% of Inovio Pharmaceuticals worth $845,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in the company. Barclays PLC increased its stake in shares of Inovio Pharmaceuticals by 15.0% during the fourth quarter. Barclays PLC now owns 39,114 shares of the biopharmaceutical company's stock worth $71,000 after buying an additional 5,111 shares during the period. Geode Capital Management LLC increased its stake in shares of Inovio Pharmaceuticals by 1.1% during the fourth quarter. Geode Capital Management LLC now owns 628,505 shares of the biopharmaceutical company's stock worth $1,150,000 after buying an additional 6,874 shares during the period. Northern Trust Corp increased its stake in shares of Inovio Pharmaceuticals by 6.4% during the fourth quarter. Northern Trust Corp now owns 219,057 shares of the biopharmaceutical company's stock worth $401,000 after buying an additional 13,269 shares during the period. Bank of New York Mellon Corp increased its stake in Inovio Pharmaceuticals by 22.4% in the first quarter. Bank of New York Mellon Corp now owns 75,422 shares of the biopharmaceutical company's stock valued at $123,000 after purchasing an additional 13,784 shares during the last quarter. Finally, XTX Topco Ltd increased its stake in Inovio Pharmaceuticals by 26.7% in the first quarter. XTX Topco Ltd now owns 66,169 shares of the biopharmaceutical company's stock valued at $108,000 after purchasing an additional 13,939 shares during the last quarter. 26.79% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several brokerages have commented on INO. Royal Bank Of Canada reiterated a "sector perform" rating and issued a $5.00 price target on shares of Inovio Pharmaceuticals in a research note on Wednesday, May 14th. HC Wainwright reiterated a "neutral" rating and issued a $3.00 price objective on shares of Inovio Pharmaceuticals in a research report on Thursday, August 14th. Wall Street Zen lowered shares of Inovio Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Saturday, August 16th. Oppenheimer reduced their target price on Inovio Pharmaceuticals from $15.00 to $13.00 and set an "outperform" rating for the company in a report on Wednesday, May 14th. Finally, Piper Sandler assumed coverage on Inovio Pharmaceuticals in a report on Wednesday, July 9th. They issued an "overweight" rating and a $5.00 target price for the company. Three research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $8.80.

Inovio Pharmaceuticals Stock Up 4.6%

Shares of INO traded up $0.09 during trading on Tuesday, reaching $2.04. The company's stock had a trading volume of 1,583,284 shares, compared to its average volume of 1,837,838. The company has a fifty day moving average of $1.65 and a two-hundred day moving average of $1.83. Inovio Pharmaceuticals, Inc. has a twelve month low of $1.30 and a twelve month high of $7.61. The company has a market cap of $108.41 million, a price-to-earnings ratio of -0.78 and a beta of 1.38.

Inovio Pharmaceuticals (NASDAQ:INO - Get Free Report) last announced its earnings results on Tuesday, August 12th. The biopharmaceutical company reported ($0.61) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.63) by $0.02. As a group, equities analysts forecast that Inovio Pharmaceuticals, Inc. will post -4.23 EPS for the current fiscal year.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.